Flow Traders U.S.’s Alnylam Pharmaceuticals ALNY Stock Holding History

Flow Traders U.S.’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,135	Closed	-$451K	–	989
2025 Q4	$451K	Buy	+1,135	New	+$502K	0.01%	601
2025 Q3	–	Sell	-740	Closed	-$241K	–	923
2025 Q2	$241K	Buy	+740	New	+$205K	0.01%	798
2025 Q1	–	Sell	-1,392	Closed	-$328K	–	906
2024 Q4	$328K	Buy	+1,392	New	+$366K	0.01%	720

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flow Traders U.S.'s ALNY Position: Q1 2026 in Review

Flow Traders U.S. sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,135 shares — an estimated $451K sold.

Flow Traders U.S. first reported a position in ALNY in Q4 2024 and held it in 3 quarters. The position peaked at $451K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Flow Traders U.S. reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Flow Traders U.S. sold 1,135 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $451K.
Flow Traders U.S. first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 3 quarters.
Flow Traders U.S.'s Alnylam Pharmaceuticals position peaked at $451K in Q4 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Flow Traders U.S.'s 13F filing for Q1 2026, filed 15 May 2026.